StreetAlpha.app
Home › Stocks › EBS

Emergent BioSolutions Inc. (EBS)

Healthcare
$5.62
▼ −3.19%
LAST CLOSE · NOV 17

Emergent BioSolutions makes naloxone overdose treatments and medical countermeasures against threats like anthrax and smallpox. It last closed at $5.62 on Nov 17, down 3.19% on the day.

AI Auto Pilots
Is EBS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$649.1M
−17.7% vs a year ago
Net income
−$260.7M
−443.5% vs a year ago
EPS (diluted)
−$4.95
−475.0% vs a year ago
Free cash flow
$188.4M
29.0% margin
Valuation
Market cap
$289.0M
51.4M shares
P/E
–
No P/E while losing money
Price to sales
0.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$175.7M
At Sep 30
Debt
$514.3M
At Sep 30
Shareholder equity
$313.2M
Buybacks
$27.2M
Last 12 months
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2021: $1.8B$1.8BFY2021FY2022: $1.1B$1.1BFY2022FY2023: $1.0B$1.0BFY2023FY2024: $1.0B$1.0BFY2024FY2025: $742.9M$742.9MFY2025

From EBS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated EBS in the past 90 days, not enough for a consensus
Average 12-month target
$16.00
▲ 184.7% upside

Based on 1 analyst who set a price target on EBS in the past 90 days. The average target is $16.00, with a high of $16.00 and a low of $16.00, compared with the last close of $5.62.

Low $16.00Avg $16.00High $16.00
Blue marker: last close $5.62
Highest target$16.00
Average target$16.00
Lowest target$16.00
Latest rating changes
Rodman & RenshawInitiated
Sep 25Buy$16
HC Wainwright & Co.Maintained
Aug 10Buy$10
DateFirmActionRatingPrice target
Sep 25Rodman & RenshawInitiatedBuy$16
Aug 10HC Wainwright & Co.MaintainedBuy$10
Loading…

Technical Analysis

EBS · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 11% below its 20 day and 15% below its 50 day average. It is 37% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the swing low (Sep 10) at $5.50, and the nearest resistance the Pivot at $5.69.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 6.8%/day
Key levels
$14.0652 week high+150.2%
$7.68200 day average+36.7%
$6.60Swing high (Sep 3)+17.4%
$6.57100 day average+16.9%
$6.4950 day average+15.5%
$6.2320 day average+10.9%
$5.83Pivot R1+3.7%
$5.69Pivot+1.2%
$5.62Last close
$5.50Swing low (Sep 10)−2.1%
$5.47Pivot S1−2.7%
$4.3652 week low−22.4%
Indicators
RSI (14)35.76Weak, oversold below 30Neutral
MACD-0.22Below its signal lineBearish
Stochastic25.4Middle of its rangeNeutral
ADX (14)25.2Trending down
Williams %R-80.1Oversold below −80, overbought above −20Oversold
CCI (20)-117.1Oversold below −100, overbought above 100Oversold
Rate of change−10.1%Change over 10 sessionsBearish
ATR (14)$0.38Typical daily range, 6.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for EBS

What happened before

See how EBS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow EBS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How EBS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in EBS in the last 90 days.

Loading…

See today’s whale options flow across the market →

EBS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●102 buying vs 96 selling
  • ▲Held by funds +2.2 pts
  • ▼Funds holding -9
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding186195−4.6%
In funds' top 10110.0%
Held by funds89.1%86.9%+2.2 pts
New / increased32 / 7031 / 68+3.0%
Reduced / sold out56 / 4062 / 26+9.1%
Put/call ratio1.720.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See EBS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EBS is in one of them and how their past EBS trades turned out.

EBS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered EBS in an article yet. Here's the latest on the wider market.

EBS Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Jan 10
Who traded EBS · since 2019
Latest 5 filings of 13
$1K – $15KTraded Dec 11, 2024Filed Jan 10, 2025
$1K – $15KTraded Nov 5, 2021Filed Dec 13, 2021
$1K – $15KTraded Oct 18, 2021Filed Nov 15, 2021
Josh GottheimerSell (partial)
$1K – $15KTraded Sep 15, 2021Filed Oct 13, 2021
Josh GottheimerSell (partial)
$1K – $15KTraded Feb 23, 2021Filed Mar 10, 2021
PersonTypeAmountTradedFiledDelay
Steve CohenD · TNSell$1K – $15KDec 11, 2024Jan 10, 202530 d
Josh GottheimerD · NJSell$1K – $15KNov 5, 2021Dec 13, 202138 d
Josh GottheimerD · NJBuy$1K – $15KOct 18, 2021Nov 15, 202128 d
Josh GottheimerD · NJSell (partial)$1K – $15KSep 15, 2021Oct 13, 202128 d
Josh GottheimerD · NJSell (partial)$1K – $15KFeb 23, 2021Mar 10, 202115 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Emergent BioSolutions

Emergent BioSolutions is a life sciences company based in Gaithersburg, Maryland, that develops and sells products for preparing for and responding to public health threats. Its main products are NARCAN nasal spray and KLOXXADO, which reverse opioid overdoses and are sold through pharmacies, health departments and community groups. It also supplies vaccines, antitoxins and antibiotics for threats such as anthrax and smallpox, mainly to government agencies, with the U.S. government as its largest customer. The company also offers contract manufacturing services to drug developers.

Headquarters
Gaithersburg, MD